OTCMKTS:EMISEmisphere Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Emisphere Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.75 +0.07 (+1.23 %) (As of 07/13/2020 09:03 AM ET) Add Compare Share Today's Range$5.57Now: $5.75▼$5.7550-Day Range$5.50MA: $5.63▼$5.8552-Week Range$3.88Now: $5.75▼$11.23Volume4,100 shsAverage Volume15,595 shsMarket Capitalization$483.17 millionP/E RatioN/ADividend YieldN/ABeta1.74 ProfileAdvanced ChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Emisphere Technologies. Previous Next 2.6 Community Rank Outperform VotesEmisphere Technologies has received 80 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEmisphere Technologies has received 76 “underperform” votes. (Add your “underperform” vote.)Community SentimentEmisphere Technologies has received 51.28% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Emisphere Technologies and other stocks. Vote “Outperform” if you believe EMIS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EMIS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEmisphere Technologies does not currently pay a dividend.Dividend GrowthEmisphere Technologies does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Emisphere Technologies insiders have not sold or bought any company stock.Percentage Held by Insiders72.90% of the stock of Emisphere Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.03% of the stock of Emisphere Technologies is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.72 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:EMIS Previous Symbol CUSIPN/A CIK805326 Webwww.emisphere.com Phone973-532-8000Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees6 Outstanding Shares84,030,000Market Cap$483.17 million Next Earnings DateN/A OptionableNot Optionable OTC:EMIS Rates by TradingView Receive EMIS News and Ratings via Email Sign-up to receive the latest news and ratings for EMIS and its competitors with MarketBeat's FREE daily newsletter. Emisphere Technologies (OTCMKTS:EMIS) Frequently Asked Questions How has Emisphere Technologies' stock been impacted by COVID-19 (Coronavirus)? Emisphere Technologies' stock was trading at $6.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EMIS shares have decreased by 10.9% and is now trading at $5.75. View which stocks have been most impacted by Coronavirus. How were Emisphere Technologies' earnings last quarter? Emisphere Technologies, Inc. (OTCMKTS:EMIS) released its earnings results on Friday, May, 12th. The company reported $0.04 earnings per share (EPS) for the quarter. The company earned $0.22 million during the quarter. View Emisphere Technologies' earnings history. Has Emisphere Technologies been receiving favorable news coverage? News stories about EMIS stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Emisphere Technologies earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Emisphere Technologies. Who are some of Emisphere Technologies' key competitors? Some companies that are related to Emisphere Technologies include Ligand Pharmaceuticals (LGND), Eidos Therapeutics (EIDX), Corcept Therapeutics (CORT), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Xencor (XNCR), I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), Myovant Sciences (MYOV), Intra-Cellular Therapies (ITCI), Madrigal Pharmaceuticals (MDGL), Y-mAbs Therapeutics (YMAB), Akebia Therapeutics (AKBA), Ironwood Pharmaceuticals (IRWD) and Epizyme (EPZM). View all competitors. What other stocks do shareholders of Emisphere Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emisphere Technologies investors own include Novo Nordisk A/S (NVO), DelMar Pharmaceuticals (DMPI), Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Capricor Therapeutics (CAPR), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Superconductor Technologies (SCON), Arbutus Biopharma (ABUS) and Aurora Cannabis (ACBFF). Who are Emisphere Technologies' key executives? Emisphere Technologies' management team includes the following people: Mr. Alan L. Rubino, CEO, Pres & Director (Age 64)Mr. Alan V. Gallantar CPA, Interim Chief Financial Officer (Age 61) What is Emisphere Technologies' stock symbol? Emisphere Technologies trades on the OTCMKTS under the ticker symbol "EMIS." How do I buy shares of Emisphere Technologies? Shares of EMIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Emisphere Technologies' stock price today? One share of EMIS stock can currently be purchased for approximately $5.75. How big of a company is Emisphere Technologies? Emisphere Technologies has a market capitalization of $483.17 million. Emisphere Technologies employs 6 workers across the globe. What is Emisphere Technologies' official website? The official website for Emisphere Technologies is www.emisphere.com. How can I contact Emisphere Technologies? Emisphere Technologies' mailing address is 4 BECKER FARM ROAD SUITE 103, ROSELAND NJ, 07068. The company can be reached via phone at 973-532-8000 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
